Brokerages predict that Scpharmaceuticals Inc (NASDAQ:SCPH) will post earnings of ($0.47) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Scpharmaceuticals’ earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.48). Scpharmaceuticals posted earnings of ($0.31) per share in the same quarter last year, which suggests a negative year over year growth rate of 51.6%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 12th.
On average, analysts expect that Scpharmaceuticals will report full year earnings of ($1.85) per share for the current fiscal year, with EPS estimates ranging from ($1.86) to ($1.84). For the next financial year, analysts expect that the firm will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.10) to ($1.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.10.
Shares of NASDAQ SCPH traded down $0.49 during mid-day trading on Thursday, hitting $5.56. 51,700 shares of the company traded hands, compared to its average volume of 60,554. Scpharmaceuticals has a 1 year low of $2.44 and a 1 year high of $6.40. The firm has a market cap of $112.41 million, a PE ratio of -3.58 and a beta of 0.94. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $4.66.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Scpharmaceuticals by 2.0% during the fourth quarter. BlackRock Inc. now owns 358,243 shares of the company’s stock valued at $1,347,000 after purchasing an additional 7,094 shares during the last quarter. Eversept Partners LP purchased a new stake in shares of Scpharmaceuticals during the second quarter valued at $556,000. Alambic Investment Management L.P. purchased a new stake in shares of Scpharmaceuticals during the second quarter valued at $191,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Scpharmaceuticals by 55.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock valued at $118,000 after purchasing an additional 13,225 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Scpharmaceuticals during the second quarter valued at $96,000. 40.24% of the stock is owned by institutional investors and hedge funds.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Read More: What are the FAANG Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.